Provided by Tiger Trade Technology Pte. Ltd.

Genmab A/S

34.11
+1.464.47%
Volume:1.98M
Turnover:66.05M
Market Cap:20.98B
PE:26.96
High:34.12
Open:32.35
Low:32.34
Close:32.65
52wk High:35.43
52wk Low:23.62
Shares:615.00M
Float Shares:604.00M
Volume Ratio:1.78
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.27
EPS(LYR):1.54
ROE:14.00%
ROA:8.79%
PB:3.52
PE(LYR):22.19

Loading ...

Genmab A/S Stock Falls Friday, Underperforms Market

Dow Jones
·
Jul 18

Genmab A/S Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Jul 16

Genmab's Darzalex Generates $4.21 Billion in Q2 Net Trade Sales

MT Newswires Live
·
Jul 15

Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Genmab (GMAB)

TIPRANKS
·
Jul 15

Genmab A/S Stock Rises Monday, Outperforms Market

Dow Jones
·
Jul 14

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Krystal Biotech (KRYS) and Denali Therapeutics (DNLI)

TIPRANKS
·
Jul 13

Genmab A/S Stock Falls Friday, Underperforms Market

Dow Jones
·
Jul 11

Genmab A/S Stock Falls Wednesday, Outperforms Market

Dow Jones
·
Jul 09

Exchange-Traded Funds Lower, Equity Futures Mixed Amid Caution Over Chip Sector Outlook

MT Newswires Live
·
Jul 07

Genmab Secures EU Approval for Drug Combination Intended for Relapsed or Refractory Follicular Lymphoma

MT Newswires Live
·
Jul 07

Genmab A/S Stock Falls Monday, Underperforms Market

Dow Jones
·
Jul 07

Genmab A/S Stock Falls Friday, Underperforms Market

Dow Jones
·
Jul 04

Genmab is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 02

Genmab A/S Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Jul 02

Abbvie, Genmab Blood-cancer Drug Has Competitive Profile

Dow Jones
·
Jun 30

Investors See European Pharma Stocks as Funding Source for AI Trades

Dow Jones
·
Jun 30

Guggenheim Reaffirms Their Buy Rating on Genmab (GMAB)

TIPRANKS
·
Jun 30

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB) and Hinge Health, Inc. Class A (HNGE)

TIPRANKS
·
Jun 30

Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial

Dow Jones
·
Jun 30

Abbvie, Genmab's Lymphoma Treatment Meets Primary Endpoint in Phase 3 Trial

Dow Jones
·
Jun 30